Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 674 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Halozyme Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 550 | 8 | 552 | +10 |
| Shares | 121.0M | 626.3K | 116.3M | −4.07M (−3.4%) |
| Value | $7.72B | $40.0M | $6.05B | −$1.63B (−21.2%) |
8 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (90)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (80)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (8)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Glenmede Trust Co NA | 499,029 | $31.8M |
| Redwood Investments, LLC | 40,335 | $2.57M |
| Credit Agricole S A | 38,855 | $2.48M |
| Orion Portfolio Solutions, LLC | 27,908 | $1.78M |
| Sheaff Brock Investment Advisors, LLC | 7,869 | $502.1K |
| Callan Capital, LLC | 6,222 | $397.0K |
| Caas Capital Management LP | 4,700 | $299.9K |
| Lindbrook Capital, LLC | 1,405 | $89.7K |